Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy;Inhibitory polimerazy poli(ADP-rybozy) (PARP) w terapii nowotworów z mutacjami BRCA1/2

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 372-384

  Kluzek, Katarzyna ^a   Białkowska, Aneta ^a   Koczorowska, Aleksandra ^a   Zdzienicka, Małgorzata Z ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Anticancer therapy; BRCA1 2; Homologous recombination; PARP inhibitors

Indexed keywords

EID: 84867975369     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1000548     Document Type: Review

References (118)

1. Althaus F. R., Kleczkowska H. E., Malanga M., Muntener C. R., Pleschke J. M., Ebner M., Auer B.: Poly ADP-ribosylation: a DNA break signal mechanism. Mol. Cell. Biochem., 1999;193:5-11
2. Altmeyer M., Messner S., Hassa P. O., Fey M., Hottiger M. O.: Molecular mechanism of poly (ADP-ribosyl) ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res., 2009;37:3723-3738
3. Amé J. C., Rolli V., Schreiber V., Niedergang C., Apiou F., Decker P., Muller S., Höger T., Ménissier-de Murcia J., de Murcia G.: PARP-2, a novel mammalian DNA damage-dependent poly (ADP-ribose) polymerase. J. Biol. Chem., 1999;274:17860-17868
4. Amé J. C., Spenlehauer C., de Murcia G.: The PARP superfamily. Bioessays, 2004;26:882-893
5. Bast R. C. Jr., Hennessy B., Mills G. B.: The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer, 2009;9:415-428
6. Beneke S., Bürkle A.: Poly (ADP-ribosyl) ation, PARP, and aging. Sci. Aging Knowledge Environ., 2004;49:re9
7. Boulton S., Pemberton L. C., Porteous J. K., Curtin N. J., Griffin R. J., Golding B. T., Durkacz B. W.: Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly-(ADP-ribose) polymerase inhibitors. Br. J. Cancer, 1995;72:849-856
8. Bryant H. E., Schultz N., Thomas H. D., Parker K. M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N. J., Helleday T.: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature, 2005;434:913-917
9. Calabrese C. R., Almassy R., Barton S., Batey M. A., Calvert A. H., Canan-Koch S., Durkacz B. W., Hostomsky Z., Kumpf R. A., Kyle S., Li J., Maegley K., Newell D. R., Notarianni E., Stratford I. J., Skalitzky D., Thomas H. D., Wang L. Z., Webber S. E., Williams K. J., Curtin N. J.: Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst., 2004;96:56-67
10. Campeau P. M., Foulkes W. D., Tischkowitz M. D.: Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum. Genet., 2008;124:31-42
11. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature, 2011;474:609-615
12. Cerbinskaite A., Mukhopadhyay A., Plummer E. R., Curtin N. J., Edmondson R. J.: Defective homologous recombination in human cancers. Cancer Treat. Rev., 2012;38:89-100
13. Chen J., Silver D. P., Walpita D., Cantor S. B., Gazdar A. F., Tomlinson G., Couch F. J., Weber B. L., Ashley T., Livingston D. M., Scully R.: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell, 1998;2:317-328
14. Coughlin S. S., Ekwueme D. U.: Breast cancer as a global health concern. Cancer Epidemiol., 2009;33:315-318
15. Curtin N. J.: PARP inhibitors for cancer therapy. Expert Rev. Mol. Med., 2005;7:1-20
16. D'Amours D., Desnoyers S., D'Silva I., Poirier G. G.: Poly (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem. J., 1999;342:249-268
17. Dantzer F., de La Rubia G., Ménissier-De Murcia J., Hostomsky Z., de Murcia G., Schreiber V.: Base excision repair is impaired in mammalian cells lacking Poly (ADP-ribose) polymerase-1. Biochemistry, 2000;39:7559-7569
18. Davidovic L., Vodenicharov M., Affar E. B., Poirier G. G.: Importance of poly (ADP-ribose) glycohydrolase in the control of poly (ADP-ribose) metabolism. Exp. Cell Res., 2001;268:7-13
19. Davies O. R., Pellegrini L.: Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat. Struct. Mol. Biol., 2007;14:475-483
20. de Jong M. M., Nolte I. M., te Meerman G. J., van der Graaf W. T., Oosterwijk J. C., Kleibeuker J. H., Schaapveld M., de Vries E. G.: Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet., 2002;39:225-242
21. de Murcia J. M., Niedergang C., Trucco C., Ricoul M., Dutrillaux B., Mark M., Oliver F. J., Masson M., Dierich A., Le Meur M., Walztinger C., Chambon P., de Murcia G.: Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. USA, 1997;94:7303-7307
22. Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A., Lickley L. A., Rawlinson E., Sun P., Narod S. A.: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res., 2007;13:4429-4434
23. Di Cosimo S., Baselga J.: Targeted therapies in breast cancer: where are we now? Eur. J. Cancer, 2008;44:2781-2790
24. Domagala P., Huzarski T., Lubinski J., Gugala K., Domagala W.: PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res. Treat., 2011;127:861-869
25. Dominguez-Bendala J., Masutani M., McWhir J.: Down-regulation of PARP-1, but not of Ku80 or DNA-PKcs', results in higher gene targeting efficiency. Cell Biol. Int., 2006;30:389-393
26. Donawho C. K., Luo Y., Luo Y., Penning T. D., Bauch J. L., Bouska J. J., Bontcheva-Diaz V. D., Cox B. F., De Weese T. L., Dillehay L. E., Ferguson D. C., Ghoreishi-Haack N. S., Grimm D. R., Guan R., Han E. K., Holley-Shanks R. R., Hristov B., Idler K. B., Jarvis K., Johnson E. F., Kleinberg L. R., Klinghofer V., Lasko L. M., Liu X., Marsh K. C., McGonigal T. P., Meulbroek J. A., Olson A. M., Palma J. P., Rodriguez L. E., Shi Y., Stavropoulos J. A., Tsurutani A. C., Zhu G. D., Rosenberg S. H., Giranda V. L., Frost D. J.: ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007;13:2728-2737
27. Dupré A., Boyer-Chatenet L., Gautier J.: Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex. Nat. Struct. Mol. Biol., 2006;13:451-457
28. Edwards S. L., Brough R., Lord C. J., Natrajan R., Vatcheva R., Levine D. A., Boyd J., Reis-Filho J. S., Ashworth A.: Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008;451:1111-1115
29. Farmer H., McCabe N., Lord C. J., Tutt A. N., Johnson D. A., Richardson T. B., Santarosa M., Dillon K. J., Hickson I., Knights C., Martin N. M., Jackson S. P., Smith G. C., Ashworth A.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005;434:917-921
30. Ferraris D. V.: Evolution of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem., 2010;53:4561-4584
31. Fong P. C., Boss D. S., Yap T. A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M. J., Ashworth A., Carmichael J., Kaye S. B., Schellens J. H., de Bono J. S.: Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009;361:123-134
32. Friedberg E. C., Meira L. B.: Database of mouse strains carrying targeted mutations in genes affecting biological responses to DNA damage Version 7. DNA Repair, 2006;5:189-209
33. Gallmeier E., Kern S. E.: Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly (ADP-ribose) polymerase inhibition. Cancer Biol. Ther., 2005;4:703-706
34. Godon C., Cordelieres F. P., Biard D., Giocanti N., Mégnin-Chanet F., Hall J., Favaudon V.: PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res., 2008;36:4454-4464
35. Goldberg M. S., Xing D., Ren Y., Orsulic S., Bhatia S. N., Sharp P. A.: Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc. Natl. Acad. Sci. USA, 2011;108:745-750
36. Gonzalez R., Silva J. M., Dominguez G., Garcia J. M., Martinez G., Vargas J., Provencio M., Espana P., Bonilla F.: Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Br. J. Cancer, 1999;81:503-509
37. Graziani G., Szabó C.: Clinical perspectives of PARP inhibitors. Pharmacol. Res., 2005;52:109-118
38. Gudmundsdottir K., Ashworth A.: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene, 2006;25:5864-5874
39. Haince J. F., Kozlov S., Dawson V. L., Dawson T. M., Hendzel M. J., Lavin M. F., Poirier G. G.: Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly (ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J. Biol. Chem., 2007;282:16441-16453
40. Haince J. F., McDonald D., Rodrigue A., Déry U., Masson J. Y., Hendzel M. J., Poirier G. G.: PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J. Biol. Chem., 2008;283:1197-1208
41. Helleday T.: Pathways for mitotic homologous recombination in mammalian cells. Mutat. Res., 2003;532:103-115
42. Helleday T.: Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis, 2010;31:955-960
43. Helleday T., Lo J., van Gent D. C., Engelward B. P.: DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair, 2007;6:923-935
44. Hinz J. M.: Role of homologous recombination in DNA interstrand crosslink repair. Environ. Mol. Mutagen., 2010;51:582-603
45. Hochegger H., Takeda S.: Phenotypic analysis of cellular responses to DNA damage. Subcell. Biochem., 2006;40:313-325
46. Holthausen J. T., Wyman C., Kanaar R.: Regulation of DNA strand exchange in homologous recombination. DNA Repair, 2010;9:1264-1272
47. Jagtap P., Szabó C.: Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov., 2005;4:421-440
48. Jones P., Altamura S., Boueres J., Ferrigno F., Fonsi M., Giomini C., Lamartina S., Monteagudo E., Ontoria J. M., Orsale M. V., Palumbi M. C., Pesci S., Roscilli G., Scarpelli R., Schultz-Fademrecht C., Toniatti C., Rowley M.: Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly (ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J. Med. Chem., 2009;52:7170-7185
49. Kaelin W. G. Jr.: The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer, 2005;5:689-698
50. Kiliańska Z. M., Żołnierczyk J., Wȩsierska- Ga̧dek J.: Biologiczna aktywność polimerazy poli (ADP-rybozy)-1. Postȩpy Hig. Med. Dośw., 2010;64:344-363
51. Kim M. Y., Zhang T., Kraus W. L.: Poly (ADP-ribosyl) ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev., 2005;19:1951-1967
52. Kraus W. L., Lis J. T.: PARP goes transcription. Cell, 2003;113:677-683
53. Lautier D., Lagueux J., Thibodeau J., Ménard L., Poirier G. G.: Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol. Cell. Biochem., 1993;122:171-193
54. Leppard J. B., Dong Z., Mackey Z. B., Tomkinson A. E.: Physical and functional interaction between DNA ligase IIIα and poly (ADP-Ribose) polymerase 1 in DNA single-strand break repair. Mol. Cell. Biol., 2003;23:5919-5927
55. Levy-Lahad E.: Fanconi anemia and breast cancer susceptibility meet again. Nat. Genet., 2010;42:368-369
56. Li X., Heyer W. D.: Homologous recombination in DNA repair and DNA damage tolerance. Cell Res., 2008;18:99-113
57. Lindahl T., Satoh M. S., Poirier G. G., Klungland A.: Post-translational modification of poly (ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci., 1995;20:405-411
58. Liu Y., West S. C.: Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res., 2002;4:9-13
59. Lord C. J., Ashworth A.: Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol., 2008;8:363-369
60. Madhusudan S., Hickson I. D.: DNA repair inhibition: a selective tumour targeting strategy. Trends Mol. Med., 2005;11:503-511
61. Marsit C. J., Liu M., Nelson H. H., Posner M., Suzuki M., Kelsey K. T.: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene, 2004;23:1000-1004
62. Martin D. R., Lewington A. J., Hammerman M. R., Padanilam B. J.: Inhibition of poly (ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000;279:R1834-R1840
63. McCabe N., Lord C. J., Tutt A. N., Martin N. M., Smith G. C., Ashworth A.: BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol. Ther., 2005;4:934-936
64. McCabe N., Turner N. C., Lord C. J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M. J., Tutt A. N., Zdzienicka M. Z., Smith G. C., Ashworth A.: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res., 2006;66:8109-8115
65. Mendoza-Alvarez H., Alvarez-Gonzalez R.: Poly (ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J. Biol. Chem., 1993;268:22575-22580
66. Menear K. A., Adcock C., Boulter R., Cockcroft X. L., Copsey L., Cranston A., Dillon K. J., Drzewiecki J., Garman S., Gomez S., Javaid H., Kerrigan F., Knights C., Lau A., Loh V. M. Jr., Matthews I. T., Moore S., O'Connor M. J., Smith G. C., Martin N. M.: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J. Med. Chem., 2008;51:6581-6591
67. Ménissier de Murcia J., Ricoul M., Tartier L., Niedergang C., Huber A., Dantzer F., Schreiber V., Amé J. C., Dierich A., Le Meur M., Sabatier L., Chambon P., de Murcia G.: Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J., 2003;22:2255-2263
68. Miknyoczki S., Chang H., Grobelny J., Pritchard S., Worrell C., McGann N., Ator M., Husten J., Deibold J., Hudkins R., Zulli A., Parchment R., Ruggeri B.: The selective poly (ADP-ribose) polymerase-1 (2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther., 2007;6:2290-2302
69. Misteli T., Soutoglou E.: The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat. Rev. Mol. Cell Biol., 2009;10:243-254
70. Moeller B. J., Yordy J. S., Williams M. D., Giri U., Raju U., Molkentine D. P., Byers L. A., Heymach J. V., Story M. D., Lee J. J., Sturgis E. M., Weber R. S., Garden A. S., Ang K. K., Schwartz D. L.: DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin. Cancer Res., 2011;17:2035-2043
71. Moynahan M. E., Jasin M.: Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol., 2010;11:196-207
72. Narayan G., Arias-Pulido H., Nandula S. V., Basso K., Sugirtharaj D. D., Vargas H., Mansukhani M., Villella J., Meyer L., Schneider A., Gissmann L., Dürst M., Pothuri B., Murty V. V.: Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res., 2004;64:2994-2997
73. Negrini S., Gorgoulis V. G., Halazonetis T. D.: Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol., 2010;11:220-228
74. O'Donovan P. J., Livingston D. M.: BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis, 2010;31:961-967
75. O'Shaughnessy J., Osborne C., Pippen J. E., Yoffe M., Patt D., Rocha C., Koo I. C., Sherman B. M., Bradley C.: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med., 2011;364:205-214
76. Oliver A. W., Swift S., Lord C. J., Ashworth A., Pearl L. H.: Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep., 2009;10:990-996
77. Otto H., Reche P. A., Bazan F., Dittmar K., Haag F., Koch-Nolte F.: In silico characterization of the family of PARP-like poly (ADP-ribosyl) transferases (pARTs). BMC Genomics, 2005;6:139
78. Panzeter P. L., Althaus F. R.: DNA strand break-mediated partitioning of poly (ADP-ribose) polymerase function. Biochemistry, 1994;33:9600-9605
79. Petermann E., Helleday T.: DNA replication-associated lesions: importance in early tumorigenesis and cancer therapy. Biochem. Soc. Trans., 2007;35:1352-1354
80. Pleschke J. M., Kleczkowska H. E., Strohm M., Althaus F. R.: Poly (ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J. Biol. Chem., 2000;275:40974-40980
81. Quénet D., Gasser V., Fouillen L., Cammas F., Sanglier-Cianferani S., Losson R., Dantzer F.: The histone subcode: poly (ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1b and the heterochromatin protein HP1a. FASEB J., 2008;22:3853-3865
82. Rankin P. W., Jacobson E. L., Benjamin R. C., Moss J., Jacobson M. K.: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J. Biol. Chem., 1989;264:4312-4317
83. Realini C. A., Althaus F. R.: Histone shuttling by poly (ADP-ribosylation). J. Biol. Chem., 1992;267:18858-18865
84. Ripperger T., Gadzicki D., Meindl A., Schlegelberger B.: Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur. J. Hum. Genet., 2009;17:722-731
85. Rouleau M., Aubin R. A., Poirier G. G.: Poly (ADP-ribosyl) ated chromatin domains: access granted. J. Cell Sci., 2004;117:815-825
86. Rupnik A., Lowndes N. F., Grenon M.: MRN and the race to the break. Chromosoma, 2010;119:115-135
87. Saeki H., Siaud N., Christ N., Wiegant W. W., van Buul P. P., Han M., Zdzienicka M. Z., Stark J. M., Jasin M.: Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl. Acad. Sci. USA, 2006;103:8768-8773
88. Sakai W., Swisher E. M., Karlan B. Y., Agarwal M. K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D. J., Couch F. J., Urban N., Taniguchi T.: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 2008;451:1116-1120
89. Sartori A. A., Lukas C., Coates J., Mistrik M., Fu S., Bartek J., Baer R., Lukas J., Jackson S. P.: Human CtIP promotes DNA end resection. Nature, 2007;450:509-514
90. Satoh M. S., Lindahl T.: Role of poly (ADP-ribose) formation in DNA repair. Nature, 1992;356:356-358
91. Schwartz E. K., Heyer W. D.: Processing of joint molecule intermediates by structure-selective endonucleases during homologous recombination in eukaryotes. Chromosoma, 2011;120:109-127
92. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., Ashley T., Livingston D. M.: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 1997;88:265-275
93. Scully R., Xie A.: BRCA1 and BRCA2 in breast cancer predisposition and recombination control. J. Mammary Gland Biol. Neoplasia, 2004;9:237-246
94. Skalitzky D. J., Marakovits J. T., Maegley K. A., Ekker A., Yu X. H., Hostomsky Z., Webber S. E., Eastman B. W., Almassy R., Li J., Curtin N. J., Newell D. R., Calvert A. H., Griffin R. J., Golding B. T.: Tricyclic benzimidazoles as potent poly (ADP-ribose) polymerase-1 inhibitors. J. Med. Chem., 2003;46:210-213
95. Ström C. E., Johansson F., Uhlén M., Szigyarto C. A., Erixon K., Helleday T.: Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res., 2011;39:3166-3175
96. Sugimura K., Takebayashi S., Taguchi H., Takeda S., Okumura K.: PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J. Cell Biol., 2008;183:1203-1212
97. Svendsen J. M., Harper J. W.: GEN1/Yen1 and the SLX4 complex: Solutions to the problem of Holliday junction resolution. Genes Dev., 2010;24:521-536
98. Sy S. M., Huen M. S., Chen J.: PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. USA, 2009;106:7155-7160
99. Tentori L., Graziani G.: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res., 2005;52:25-33
100. Tentori L., Portarena I., Torino F., Scerrati M., Navarra P., Graziani G.: Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G (2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia, 2002;40:44-54
101. Thomas H. D., Calabrese C. R., Batey M. A., Canan S., Hostomsky Z., Kyle S., Maegley K. A., Newell D. R., Skalitzky D., Wang L. Z., Webber S. E., Curtin N. J.: Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther., 2007;6:945-956
102. Thorslund T., West S. C.: BRCA2: a universal recombinase regulator. Oncogene, 2007;26:7720-7730
103. Timinszky G., Till S., Hassa P. O., Hothorn M., Kustatscher G., Nijmeijer B., Colombelli J., Altmeyer M., Stelzer E. H., Scheffzek K., Hottiger M. O., Ladurner A. G.: A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat. Struct. Mol. Biol., 2009;16:923-929
104. Tulin A., Spradling A.: Chromatin loosening by poly (ADP)-ribose polymerase (PARP) at Drosophila puff loci. Science, 2003;299:560-562
105. Turnbull C., Hodgson S.: Genetic predisposition to cancer. Clin. Med., 2005;5:491-498
106. Turner N., Tutt A., Ashworth A.: Targeting the DNA repair defect of BRCA tumours. Curr. Opin. Pharmacol., 2005;5:388-393
107. Tutt A.: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer 2009 ASCO Annual Meeting 2009
108. Tutt A., Ashworth A.: The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med., 2002;8:571-576
109. Uringa E. J., Youds J. L., Lisaingo K., Lansdorp P. M., Boulton S. J.: RTEL1: an essential helicase for telomere maintenance and the regulation of homologous recombination. Nucleic Acids Res., 2011;39:1647-1655
110. Virág L., Szabó C.: The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol. Rev., 2002;54:375-429
111. Wiegant W. W., Overmeer R. M., Godthelp B. C., van Buul P. P., Zdzienicka M. Z.: Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function. Mutat. Res., 2006;600:79-88
112. Yap T. A., Sandhu S. K., Carden C. P., de Bono J. S.: Poly (ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin., 2011;61:31-49
113. Yoshida K., Miki Y.: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci., 2004;95:866-871
114. Yoshikawa K., Ogawa T., Baer R., Hemmi H., Honda K., Yamauchi A., Inamoto T., Ko K., Yazumi S., Motoda H., Kodama H., Noguchi S., Gazdar A. F., Yamaoka Y., Takahashi R.: Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int. J. Cancer, 2000;88:28-36
115. You Z., Bailis J. M.: DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol., 2010;20:402-409
116. Yun M. H., Hiom K.: CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature, 2009;459:460-463
117. Zahradka P., Ebisuzaki K.: A shuttle mechanism for DNA-protein interactions. The regulation of poly (ADP-ribose) polymerase. Eur. J. Biochem., 1982;127:579-585
118. Zhang F., Fan Q., Ren K., Andreassen P. R.: PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res., 2009;7:1110-1118